Advancing Access to Biologic Medicines
Samsung Bioepis (samsungbioepis.com) scores 68 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, Manufacturing brands, in the 17th percentile of 16341 Healthcare brands.
Samsung Bioepis, founded in 2012 and headquartered in Incheon, South Korea, is a biopharmaceutical company specializing in the development and commercialization of biosimilars. Its mission is to improve patient access to high-quality biologic treatments by offering cost-effective alternatives to original biologic drugs. The company serves healthcare providers, patients, payers, and pharmaceutical partners, leveraging advanced biotechnology and strict quality standards to produce biosimilars that match the efficacy and safety of reference biologics.
| Brand Name | Samsung Bioepis |
|---|---|
| Domain | samsungbioepis.com |
| Industry | Healthcare, Manufacturing |
| Founded | 2012 |
| Headquarters | Incheon |
| Parent Company / Owner | Samsung |
| Main Competitors | Celltrion (80/100), Sandoz (87/100), Amgen (90/100), Viatris (90/100), Biocon Biologics (73/100), Boehringer Ingelheim (76/100), Pfizer (89/100) |
Moz Domain Authority 43/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,505,764 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Samsung Bioepis has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "To improve patient access to high-quality biopharmaceuticals through the development of biosimilars." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Content is KO-only, limiting citation in English-language AI answers.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, YouTube; no detected presence on Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Samsung Bioepis?", Claude could identify the brand as of October 2026. Samsung Bioepis is a biopharmaceutical company founded in 2012 as a joint venture between Samsung BioLogics and Biogen, focused on developing biosimilars for autoimmune diseases, oncology, and ophthalmology. It has brought to market biosimilars of drugs like Humira, Herceptin, Av Best known for Developing and commercializing biosimilars for major biologic drugs like Humira, Herceptin, and Avastin.
When asked "Best brands similar to Samsung Bioepis?", Claude would recommend Samsung Bioepis as of October 2026. It's one of the leading global biosimilar makers with a strong track record of regulatory approvals, so it would naturally come up alongside companies like Celltrion and Sandoz.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Samsung Bioepis's main competitors in Healthcare: Celltrion (80/100), Sandoz (87/100), Amgen (90/100), Viatris (90/100), Biocon Biologics (73/100).
Sources: Brand Analyzer scan
Samsung Bioepis offers biosimilars-biologic pharmaceutical products developed to be highly similar to already-approved reference biologic drugs. These products are designed to provide the same efficacy and safety profiles as the original biologics but at a more accessible cost, serving the needs of healthcare providers, patients, payers, and pharmaceutical partners seeking cost-effective biologic treatment options.
Sources: Samsung Bioepis official site
Samsung Bioepis is a biopharmaceutical company founded in 2012 and headquartered in Incheon, South Korea, that specializes in the development of biosimilars-biologic medical products highly similar to already approved reference biologics. The company focuses on making high-quality biologic treatments more accessible to patients by creating alternatives to expensive original biologic drugs.
Sources: Samsung Bioepis official site
Samsung Bioepis has limited AI-search visibility, scoring 45/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 22, recommendation 39). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Samsung Bioepis official site
Samsung Bioepis was founded in 2012. Samsung Bioepis operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Samsung Bioepis is headquartered in Incheon. Samsung Bioepis operates in the Healthcare category.
Sources: Wikidata
Samsung Bioepis develops and commercializes biosimilars, which are biologic drugs designed to match the efficacy and safety profile of original reference biologics. The company uses advanced biotechnology and rigorous quality standards throughout its development process to create these products, aiming to provide more affordable treatment options for patients while maintaining clinical equivalence to the original biologic drugs.
Sources: Samsung Bioepis official site
Samsung Bioepis scores 39/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Samsung Bioepis official site
Samsung Bioepis can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Samsung Bioepis official site
Samsung Bioepis's offerings are used by healthcare providers, patients, payers, and pharmaceutical partners who are seeking cost-effective biologic treatment options. These stakeholders benefit from biosimilars that provide comparable efficacy and safety to original biologic drugs at a more accessible cost.
Sources: Samsung Bioepis official site
Samsung Bioepis is known for its work in the biosimilar development space, positioning itself as a global leader that combines advanced biotechnology with a focus on affordability in healthcare. The company is recognized for its mission-driven approach to improving patient access to biologic treatments through the creation of cost-effective biosimilar alternatives.
Sources: Samsung Bioepis official site
Samsung Bioepis scores 45/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Samsung Bioepis has a limited AI-visibility profile at 45/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (22/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #1,505,764 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Samsung Bioepis from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Samsung Bioepis: Pillr Health (68/100), Pillr Health (68/100), Sandnes kommune (68/100), Sanofi (68/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.